By NeuroPept Labs Research TeamIn Nootropic Peptides, Research Peptides0 Comments

Selank: Anxiolytic & Nootropic Peptide Research

07/14/2026

Selank: Anxiolytic & Nootropic Peptide Research

Research-only note: This article is for educational purposes and discusses a compound intended strictly for in vitro and laboratory research. The information below is not medical advice, and the products referenced are not for human consumption.

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from the endogenous immunomodulatory peptide tuftsin, studied extensively in anxiolytic, nootropic, and neuroimmune research. By appending a stabilizing Pro-Gly-Pro tripeptide to the tuftsin core, it gains far greater metabolic stability than the native molecule — and in research models it produces calming, anti-anxiety effects without the sedation or dependence associated with conventional anxiolytics.

Key takeaways

What it is: a synthetic heptapeptide analog of the immune peptide tuftsin.
Anxiolytic focus: studied for anti-anxiety effects via GABA and serotonin modulation.
Non-sedating: in models, calming effects occur without sedation or dependence.
Neuroimmune: its tuftsin origin links it to immunomodulatory signaling.
Neurotrophic: associated with increased BDNF expression.
Format: supplied as a lyophilized powder with batch-specific third-party analytics.

What is Selank?

Selank is a short synthetic peptide built from tuftsin — a naturally occurring four-amino-acid immune peptide (Thr-Lys-Pro-Arg) — with an added C-terminal Pro-Gly-Pro tripeptide. As with related peptides, that terminal extension is there for stability: native tuftsin is broken down quickly, while the modified analog persists long enough to be a practical research tool. Its defining features are:

Heptapeptide structure — a seven-amino-acid sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro.
Tuftsin-derived — based on an endogenous immunomodulatory peptide.
Metabolically stable — the Pro-Gly-Pro extension resists enzymatic degradation.
Dual character — carries both neuroactive and immune-related properties.

NeuroPept Labs supplies the compound as a research-grade lyophilized peptide verified through independent analytical testing. The published literature is indexed in the PubMed database.

Mechanism of action

Selank’s anxiolytic reputation in research comes from acting on several neurochemical systems at once rather than a single receptor. The mechanisms most often described are:

GABAergic modulation — influencing the brain’s primary inhibitory system, associated with reduced anxiety.
Serotonergic activity — modulating serotonin metabolism linked to mood and calm.
Enkephalin stabilization — inhibiting enzymes that degrade endogenous regulatory peptides, prolonging their effects.
BDNF signaling — associated with increased brain-derived neurotrophic factor in models.

The combination of GABAergic and serotonergic modulation is what underlies the calming profile, while the enkephalin and BDNF effects connect it to broader nootropic research.

The tuftsin connection: a neuroimmune angle

What sets Selank apart from purely neuroactive peptides is its origin in tuftsin, an immune-signaling molecule. This gives it a neuroimmune dimension that is a distinct research focus:

Immunomodulation — tuftsin-derived activity links it to immune-cell signaling.
Cytokine effects — studied for influence on cytokine and interferon-related pathways.
Stress-immune interface — examined where anxiety, stress, and immune function intersect.
Dual research value — relevant to both neuroscience and neuroimmunology.

This neuroimmune character means Selank is studied not only as an anxiolytic tool but also as a probe for how stress and immune signaling interact — a connection few small peptides offer. The link is not incidental: because chronic stress is known to influence immune function, a molecule that touches both systems provides a rare opportunity to study that crosstalk directly. In practice, researchers can examine whether an anxiolytic signal and an immune-modulating signal share a common upstream mechanism, or whether they operate in parallel, using a single well-characterized compound rather than combining several tools with overlapping effects.

Why “non-sedating” matters in research

A recurring point in Selank research is that its calming effects, in models, are not accompanied by the sedation, cognitive dulling, or dependence associated with conventional anxiolytics. For researchers this profile is significant:

No sedation — calming without the drowsiness typical of GABA-A-targeting drugs.
No dependence signal — models do not show the tolerance and withdrawal pattern of benzodiazepines.
Preserved cognition — anxiolytic effects without the cognitive impairment seen with sedatives.
Cleaner behavioral data — reduced confounding from sedation in behavioral models.

This separation of anxiolysis from sedation is precisely why the peptide draws interest as a research tool for studying anxiety mechanisms distinct from classical sedative pathways.

Research applications

Current laboratory and preclinical investigation involving Selank spans several neuroscience and neuroimmune domains. The following reflect documented research directions, not therapeutic claims:

Anxiety models — studying anxiolytic effects and their neurochemical basis.
Stress research — examining responses to stress and stress-related signaling.
Cognition — investigating nootropic and memory-related effects.
Neuroimmunology — mapping the tuftsin-derived immune signaling.
Mood-related pathways — assessing serotonergic contributions.

The endpoints researchers commonly track make these effects measurable:

Anxiety-behavior measures — performance in established behavioral models.
Neurotransmitter levels — GABA and serotonin dynamics.
BDNF expression — neurotrophic-factor readouts.
Cytokine profiles — immune markers reflecting the neuroimmune angle.

Across these areas, the peptide is valued for pairing an anxiolytic profile with neuroimmune activity, giving researchers a single tool that spans two fields. The anxiolytic literature is indexed in the PubMed database.

Selank vs Semax at a glance

Selank and Semax are frequently studied together as complementary Russian-developed research peptides, and comparing them clarifies their distinct roles:

Feature	Selank	Semax
Origin sequence	Tuftsin	ACTH(4-10)
Primary emphasis	Anxiolytic, calm	Cognition, neuroprotection
Key signaling	GABA/serotonin, neuroimmune	BDNF/NGF, monoamines
Shared trait	Heptapeptide, Pro-Gly-Pro stabilized, non-sedating research tool

The two are complementary: one is emphasized for calm and neuroimmune signaling, the other for cognition and neuroprotection, which is why research designs frequently include both to contrast their profiles. For a related example of endogenous neuropeptide signaling, see our overview of oxytocin mechanisms.

How Selank differs from conventional anxiolytics in models

Part of what makes this peptide a distinctive research tool is how its profile contrasts with classical anxiolytics in preclinical comparison:

Property	Selank (in models)	Classical sedative anxiolytics
Anxiolytic effect	Present	Present
Sedation	Minimal	Common
Dependence pattern	Not observed	Characteristic
Cognitive effect	Preserved or nootropic	Often impairing
Immune dimension	Neuroimmune activity	Absent

This comparison is why the peptide is studied as a mechanistically distinct approach to anxiety research rather than simply another sedative: its calming effect and its cognitive and immune profiles come apart in a way that classical compounds do not, which makes it a useful tool for probing anxiety mechanisms independent of sedative pathways.

Handling, reconstitution, and quality verification

Selank is supplied as a lyophilized powder, and its integrity affects the validity of behavioral and neurochemical models:

Storage — keep the lyophilized vial cold and protected from light until use.
Reconstitution — add diluent slowly down the vial wall and swirl gently rather than shaking.
Concentration records — note exact concentrations so signaling models are accurate.
Documentation — confirm a batch-specific certificate of analysis (COA).

Every NeuroPept Labs batch is synthesized under controlled conditions and accompanied by a COA, verifiable at freedomdiagnosticstesting.com using the codes in the product images. For the analytics behind those documents, see our research-grade quality guide.

Considerations for experimental design

Studying an anxiolytic neuroimmune peptide requires design that respects both of its dimensions:

Behavioral rigor — validated anxiety and stress models with appropriate controls.
Sedation checks — confirm anxiolytic effects are separated from sedation.
Neuroimmune readouts — include immune markers when the tuftsin angle is relevant.
Verified material — high-purity peptide ensures observed effects reflect the compound itself.

With those controls, a Selank study can distinguish a genuine anxiolytic signal from general sedation and connect it, where relevant, to the peptide’s neuroimmune origins rather than to broad experimental conditions. That distinction is the whole point of studying a non-sedating anxiolytic: if a calming effect cannot be separated from drowsiness, the finding says little about anxiety mechanisms specifically. Careful behavioral controls and verified material are what let researchers claim, with confidence, that an observed effect reflects genuine anxiolytic signaling rather than a peptide simply slowing an animal down.

Frequently asked questions

What is Selank used for in research?

In research, Selank is studied as an anxiolytic and nootropic peptide, with a focus on GABA and serotonin modulation, BDNF signaling, and its tuftsin-derived neuroimmune activity. It is used in anxiety, stress, and neuroimmune models and is for in vitro and laboratory research only.

How does Selank produce anxiolytic effects without sedation?

In research models, Selank modulates GABAergic and serotonergic systems in a way that reduces anxiety-related behavior without the sedation, cognitive dulling, or dependence pattern associated with conventional GABA-A-targeting anxiolytics.

What is the tuftsin connection?

Selank is derived from tuftsin, an endogenous immunomodulatory peptide, which gives it a neuroimmune dimension. This is why it is studied not only for anxiety but also for immune-related signaling.

What is the difference between Selank and Semax?

Both are synthetic heptapeptides studied as research nootropics, but Selank is tuftsin-derived and emphasized for anxiolytic and neuroimmune effects, while Semax is ACTH(4-10)-derived and emphasized for cognition and neuroprotection. They are often compared as complementary tools.

What form does research-grade Selank come in?

It is supplied as a lyophilized (freeze-dried) peptide powder that is reconstituted before laboratory use and stored under refrigeration, accompanied by a batch-specific certificate of analysis from an independent laboratory.

Is Selank approved for human use?

No. Selank offered for research is intended strictly for in vitro and laboratory investigation and is not approved for human consumption or clinical use. All information here is educational and not medical advice.

By NeuroPept Labs Research TeamIn Nootropic Peptides, Research & Education, Research & Education, Research Peptides0 Comments

Semax: Nootropic & Neuroprotective Peptide Research

07/13/2026

Semax: Nootropic & Neuroprotective Peptide Research

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4-10) fragment of adrenocorticotropic hormone, studied extensively as a neuroprotective and nootropic research compound. Unlike the parent hormone, it lacks corticotropic (stress-hormone) activity, so in research models it influences neurotrophic and monoaminergic pathways without activating the cortisol axis — the property that makes it a focused tool for cognition and neuroprotection research.

Key takeaways

What it is: a synthetic heptapeptide analog of the ACTH(4-10) fragment.
No corticotropic effect: influences the brain without activating the cortisol/stress axis.
Neurotrophic: studied for increasing BDNF and NGF expression.
Monoaminergic: modulates dopamine and serotonin signaling in models.
Stability: a Pro-Gly-Pro terminal extension resists enzymatic degradation.
Format: supplied as a lyophilized powder with batch-specific third-party analytics.

What is Semax?

Semax is a short synthetic peptide built from the 4-10 sequence of ACTH with an added C-terminal Pro-Gly-Pro tripeptide. That structure is deliberate: the ACTH(4-10) core carries the neurotropic activity, while the appended tripeptide protects the molecule from rapid breakdown. Its defining features are:

Heptapeptide structure — a seven-amino-acid sequence, Met-Glu-His-Phe-Pro-Gly-Pro.
ACTH(4-10) derived — based on the neuroactive fragment of adrenocorticotropic hormone.
Non-hormonal — retains neurotropic activity without the parent hormone’s corticotropic effect.
Enzyme-resistant — the Pro-Gly-Pro extension extends its functional stability.

NeuroPept Labs supplies the compound as a research-grade lyophilized peptide verified through independent analytical testing. The published literature is indexed in the PubMed database.

Mechanism of action

Semax’s research interest comes from acting on the brain through several complementary pathways rather than a single receptor. The mechanisms most often described in the literature are:

Neurotrophic signaling — increasing expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), which support neuron survival and plasticity.
Monoaminergic modulation — influencing dopamine and serotonin systems associated with attention and mood.
Enkephalin protection — inhibiting enzymes that degrade endogenous regulatory peptides, prolonging their activity.
Neuroprotection — antioxidant and anti-apoptotic effects studied in models of neural stress.

The combination of raising neurotrophic factors while modulating monoamine systems is what underlies the compound’s dual reputation as both a neuroprotective and a nootropic research tool.

Why the absence of corticotropic activity matters

A central point in Semax research is that it is derived from ACTH but does not act like it hormonally. Full ACTH stimulates the adrenal glands to release cortisol; the 4-10 fragment used here carries the neural activity without that endocrine effect. For researchers this separation is valuable:

Cleaner interpretation — neural effects are not confounded by a cortisol response.
No HPA activation — the hypothalamic-pituitary-adrenal stress axis is not engaged.
Focused tool — it isolates neurotrophic and monoaminergic signaling for study.

This is why Semax is described as a neuropeptide research tool rather than a hormone: it borrows a hormonal sequence but behaves in the nervous system, not the endocrine system.

Research applications

Current laboratory and preclinical investigation involving Semax spans several neuroscience domains. The following reflect documented research directions, not therapeutic claims:

Cognition and memory — studying learning, memory consolidation, and attention in models.
Neuroprotection — examining neuronal survival under ischemic or oxidative stress.
BDNF and plasticity — mapping neurotrophic signaling and synaptic plasticity.
Attention and focus — investigating monoaminergic contributions to attentional performance.
Mood-related signaling — assessing serotonergic and dopaminergic modulation.

The endpoints researchers commonly track in these models make the effects measurable:

BDNF and NGF expression — neurotrophic-factor levels as a core molecular readout.
Cognitive and behavioral measures — learning and memory-task performance in models.
Neuronal survival — cell viability under ischemic or oxidative stress.
Monoamine dynamics — dopamine and serotonin levels tied to attention and mood.

Across these areas, the peptide is valued for influencing multiple neural pathways at once while leaving the endocrine axis untouched — a profile that makes it a versatile probe for brain research. The neuroprotection literature is indexed in the PubMed database.

Semax and the broader neuropeptide landscape

Semax is often studied alongside other regulatory neuropeptides, because comparing them clarifies how different sequences shape brain signaling. Two useful reference points are:

Selank — a tuftsin-derived heptapeptide studied mainly for anxiolytic effects, frequently compared with Semax as a complementary nootropic tool.
Endogenous neuropeptides — molecules such as oxytocin illustrate how short peptides can exert broad, receptor-specific effects in the brain.

For a related example of neuropeptide signaling, see our research overview of oxytocin mechanisms. Researchers often pair Semax and Selank in study designs to contrast cognitive and anxiolytic profiles.

Delivery and stability in research

A practical reason for the compound’s popularity as a research tool is its stability, which stems from the Pro-Gly-Pro extension that protects it from peptidase degradation. This stability shapes how it is studied:

Intranasal models — much research uses intranasal delivery, which allows the peptide to reach the central nervous system relatively directly in animal models.
Metabolic resistance — the terminal tripeptide slows enzymatic breakdown, extending the functional window.
Rapid central action — studies report a relatively fast onset of central effects in models.
Reproducible exposure — predictable stability supports consistent experimental exposure across runs.

These properties are part of why such a short peptide can be studied as a practical central-nervous-system research tool rather than a fragile laboratory curiosity.

Semax vs Selank at a glance

Because the two are so often studied together, a direct comparison clarifies their distinct profiles:

Feature	Semax	Selank
Origin sequence	ACTH(4-10)	Tuftsin
Primary emphasis	Cognition, neuroprotection	Anxiolytic, calm
Key signaling	BDNF/NGF, monoamines	GABA/serotonin, neuroimmune
Shared trait	Heptapeptide, Pro-Gly-Pro stabilized, non-sedating research tool

The two are complementary rather than interchangeable: one leans toward cognitive and protective signaling, the other toward calming and neuroimmune effects, which is why research designs frequently include both. Studying them side by side also helps researchers separate general “short peptide reaches the brain” effects from the specific contributions of each sequence, since the shared structural backbone lets many other variables be held constant across the comparison.

Handling, reconstitution, and quality verification

Semax is supplied as a lyophilized powder, and its integrity affects the validity of neuroscience models:

Storage — keep the lyophilized vial cold and protected from light until use.
Reconstitution — add diluent slowly down the vial wall and swirl gently rather than shaking.
Concentration records — note exact concentrations so signaling models are accurate.
Documentation — confirm a batch-specific certificate of analysis (COA).

Considerations for experimental design

Studying a multi-pathway neuropeptide requires design that can separate its several actions:

Defined endpoints — choose specific markers such as BDNF expression or a behavioral cognition measure.
Pathway controls — account for neurotrophic versus monoaminergic contributions.
Model relevance — select cognition, ischemia, or plasticity models that match the question.
Verified material — high-purity peptide ensures observed effects reflect the compound itself.

With those controls, a Semax study can attribute a specific outcome to a defined pathway rather than to the compound’s broad activity in general. This precision matters because a molecule that touches neurotrophic, monoaminergic, and neuroprotective systems at once can easily produce results that look impressive but are hard to interpret. A well-designed study isolates one thread at a time — measuring a neurotrophic factor here, a behavioral endpoint there — so that the broad activity resolves into a set of specific, reproducible findings. That discipline, paired with verified starting material, is what turns a versatile but complex research tool into a source of durable data rather than intriguing but ambiguous observations.

Frequently asked questions

What is Semax used for in research?

In research, Semax is studied as a neuroprotective and nootropic peptide, with a focus on BDNF and NGF signaling, monoaminergic modulation, cognition, and neuroprotection. It is used in neuroscience models and is for in vitro and laboratory research only.

Does Semax affect cortisol?

No. Although Semax is derived from the ACTH(4-10) fragment, it lacks the corticotropic activity of full ACTH, so in research models it influences neural pathways without activating the cortisol/stress axis.

How does Semax work?

Semax is studied for increasing neurotrophic factors such as BDNF and NGF, modulating dopamine and serotonin systems, and protecting endogenous regulatory peptides from degradation, together producing neuroprotective and nootropic effects in models.

What is the difference between Semax and Selank?

Both are synthetic heptapeptides studied as nootropics, but Semax is derived from ACTH(4-10) and emphasized for cognition and neuroprotection, while Selank is derived from tuftsin and emphasized for anxiolytic effects. They are often compared as complementary tools.

What form does research-grade Semax come in?

Is Semax approved for human use?

No. Semax offered for research is intended strictly for in vitro and laboratory investigation and is not approved for human consumption or clinical use. All information here is educational and not medical advice.

By NeuroPept Labs Research TeamIn Glow, Repair & Recovery Peptides, Research & Education, Research & Education, Research Peptides0 Comments

KLOW Blend: GHK-Cu, TB-500, BPC-157 & KPV Research

07/09/2026

KLOW Blend: GHK-Cu, TB-500, BPC-157 & KPV Research

The KLOW blend combines four extensively studied research peptides — GHK-Cu, TB-500, BPC-157, and KPV — into a single 80mg lyophilized compound. It extends the well-known GLOW blend by adding KPV, layering targeted anti-inflammatory activity on top of a tissue-repair foundation. That pairing of repair and inflammation control in one preparation is what makes KLOW a distinctive tool in recovery-focused research.

Key takeaways

Four peptides: GHK-Cu (50mg), TB-500 (10mg), BPC-157 (10mg), and KPV (10mg).
Extends GLOW: the GLOW repair trio plus KPV’s anti-inflammatory action.
Repair + inflammation: combines tissue-repair signaling with inflammation control.
Complementary mechanisms: each peptide addresses a different part of the process.
Defined ratio: a single preparation with a known composition.
Format: supplied as an 80mg lyophilized blend with batch-specific third-party analytics.

What is the KLOW blend?

KLOW is a four-peptide research blend assembled around the theme of tissue repair and inflammation control. Its composition is defined and deliberate — three repair-and-regeneration peptides plus one anti-inflammatory peptide:

GHK-Cu (50mg) — a copper tripeptide studied for collagen and extracellular-matrix synthesis.
TB-500 (10mg) — a thymosin beta-4 fragment studied for cell migration and tissue organization.
BPC-157 (10mg) — a body-protection compound studied for angiogenesis and growth-factor signaling.
KPV (10mg) — an alpha-MSH tripeptide studied for anti-inflammatory signaling.

NeuroPept Labs supplies the blend as research-grade lyophilized material verified through independent analytical testing. The literature on these compounds is indexed in the PubMed database.

The four components and their roles

The logic of KLOW is that tissue repair is a multi-stage process, and each peptide is studied for a different part of it. Placed together, their roles are complementary rather than overlapping:

Peptide	Amount	Primary research role
GHK-Cu	50mg	Collagen and matrix synthesis
TB-500	10mg	Cell migration, tissue organization
BPC-157	10mg	Angiogenesis, growth-factor signaling
KPV	10mg	Anti-inflammatory signaling

Reading the table, the design becomes clear: three peptides build and organize new tissue and its blood supply, while the fourth works to keep inflammation in check during that process.

How KLOW extends the GLOW blend

KLOW is best understood in relation to the GLOW blend, which contains the same three repair peptides — GHK-Cu, TB-500, and BPC-157 — without KPV. The difference is the addition of the anti-inflammatory component:

Shared repair base — both blends contain the GHK-Cu, TB-500, and BPC-157 repair trio.
Added anti-inflammatory — KLOW adds KPV, targeting inflammatory signaling.
Broader coverage — repair and inflammation control in a single preparation.
Research rationale — inflammation and repair are intertwined, so studying them together is informative.

In short, KLOW is GLOW plus a dedicated anti-inflammatory peptide — a design choice reflecting that tissue repair rarely happens in isolation from inflammation.

KLOW vs GLOW at a glance

For researchers deciding between the two blends, the comparison is straightforward:

Feature	GLOW	KLOW
GHK-Cu	Yes	Yes
TB-500	Yes	Yes
BPC-157	Yes	Yes
KPV	No	Yes
Emphasis	Tissue repair	Repair + anti-inflammatory

The choice comes down to the research question: GLOW for repair-focused work, KLOW when anti-inflammatory activity is also part of the design.

How the components work together across the healing timeline

The rationale for combining these four peptides becomes clearest when repair is viewed as a timeline rather than a single event. Each component is studied for a phase that overlaps with the others:

Early inflammation — KPV’s anti-inflammatory signaling is studied for moderating the initial inflammatory response, while BPC-157 begins growth-factor signaling.
Angiogenesis — BPC-157’s vascular signaling supports new blood vessels to supply the repair site.
Cell migration — TB-500’s actin-related activity supports the movement of repair cells into the area.
Matrix synthesis — GHK-Cu supports collagen and extracellular-matrix formation as new tissue is built.

Viewed this way, the blend is not four peptides doing the same thing more strongly; it is four peptides each mapped onto a different, overlapping stage of the same process — with inflammation control running alongside the repair signaling rather than only after it. That temporal overlap is precisely what a combined preparation is designed to let researchers observe.

Why a combined blend is studied

Research interest in a multi-peptide blend rests on the idea that the stages of tissue repair are interconnected, and studying them together can reveal interactions that single peptides miss:

Overlapping phases — inflammation, angiogenesis, cell migration, and matrix synthesis occur together during repair.
Defined composition — a fixed ratio reduces preparation variability across runs.
Interaction research — a blend allows study of how the mechanisms combine.
Practical efficiency — one preparation instead of four separate reconstitutions.

The trade-off, which careful researchers keep in mind, is that a blend makes it harder to attribute a specific effect to a single peptide — a point that shapes how such studies are designed. For questions about the combined system, that is an acceptable and even desirable trade; for questions about a single mechanism, a blend is the wrong tool, and an individual peptide should be studied instead. Choosing between the two comes down to whether the research is asking how the parts interact or what one part does on its own.

Research applications

Current preclinical investigation involving KLOW and its component peptides spans several repair-and-inflammation domains. The following reflect documented research directions, not therapeutic claims:

Tissue repair — connective-tissue, tendon, and wound-repair models.
Inflammation control — studying anti-inflammatory contributions to repair.
Angiogenesis — new blood-vessel formation at repair sites.
Collagen and matrix — structural tissue synthesis and organization.
Combined-mechanism studies — how repair and anti-inflammatory signaling interact.

The endpoints researchers commonly track make these effects measurable:

Wound-closure rate — how quickly a repair site resolves.
Vessel density — an angiogenesis readout.
Collagen organization — the structure of new tissue.
Inflammatory markers — cytokine levels reflecting the KPV contribution.

For the individual mechanisms behind the blend, our guides on the GLOW blend and its components provide deeper background.

Handling, reconstitution, and quality verification

The KLOW blend is supplied as an 80mg lyophilized preparation, and its integrity affects the validity of repair models:

Storage — keep the lyophilized vial cold and protected from light until use.
Reconstitution — add diluent slowly down the vial wall and swirl gently rather than shaking.
Concentration records — note the reconstituted concentration for the blend as a whole.
Documentation — confirm a batch-specific certificate of analysis (COA).

Considerations for experimental design

Studying a four-peptide blend requires design that accounts for its combined nature:

Component controls — where feasible, single-peptide arms help attribute effects.
Phase-appropriate endpoints — measure inflammation, angiogenesis, and matrix at the phases where each is expected.
Fixed-ratio awareness — the blend delivers a set proportion, which shapes interpretation.
Verified material — high-purity peptides ensure observed effects reflect the blend itself.

With those controls, a KLOW study can characterize how repair and anti-inflammatory signaling combine, while remaining honest about the limits of attributing any single result to one of the four peptides. This is the central tension of blend research: a combined preparation is closer to how repair actually unfolds, with many processes active at once, but that same realism makes clean attribution harder. The most useful studies embrace the blend for what it is — a model of combined signaling — and pair it, where the question demands, with single-component work that pins down which peptide drives which effect.

Frequently asked questions

What is the KLOW blend used for in research?

In research, the KLOW blend is studied as a combined tissue-repair and anti-inflammatory compound, pairing the repair peptides GHK-Cu, TB-500, and BPC-157 with the anti-inflammatory peptide KPV. It is used in repair and inflammation models and is for in vitro and laboratory research only.

What is the difference between KLOW and GLOW?

GLOW contains three repair peptides — GHK-Cu, TB-500, and BPC-157 — while KLOW adds a fourth, KPV, for anti-inflammatory signaling. KLOW is essentially GLOW plus a dedicated anti-inflammatory component.

What peptides are in the KLOW blend?

KLOW contains GHK-Cu (50mg), TB-500 (10mg), BPC-157 (10mg), and KPV (10mg), for a total of 80mg of lyophilized research peptide in a defined ratio.

Why combine four peptides in one blend?

Because tissue repair involves overlapping stages — inflammation, angiogenesis, cell migration, and matrix synthesis — a blend lets researchers study how these complementary mechanisms interact in a single, defined-ratio preparation.

What form does the research-grade KLOW blend come in?

It is supplied as an 80mg lyophilized (freeze-dried) blend that is reconstituted before laboratory use and stored under refrigeration, accompanied by a batch-specific certificate of analysis from an independent laboratory.

Is the KLOW blend approved for human use?

No. The KLOW blend offered for research is intended strictly for in vitro and laboratory investigation and is not approved for human consumption or clinical use. All information here is educational and not medical advice.

By NeuroPept Labs Research TeamIn CJC-1295, Growth Hormone Peptides, Ipamorelin, Research Peptides0 Comments

CJC-1295 + Ipamorelin: How the GH-Axis Stack Works in Research

07/08/2026

CJC-1295 + Ipamorelin: How the GH-Axis Stack Works in Research

Research-only note: This article is for educational purposes and discusses compounds intended strictly for in vitro and laboratory research. The information below is not medical advice, and the products referenced are not for human consumption.

The CJC-1295 and Ipamorelin combination is one of the most frequently studied growth-hormone (GH) peptide stacks in preclinical research. It pairs two compounds that act on entirely separate receptor systems: CJC-1295, a growth hormone-releasing hormone (GHRH) analog that signals the pituitary to produce GH, and Ipamorelin, a selective ghrelin-receptor agonist that signals it to release GH. Because the two signals are complementary rather than redundant, research models pair them to study amplified, more physiological GH pulses than either peptide generates alone.

Key takeaways

Two pathways, one axis: CJC-1295 acts on the GHRH receptor; Ipamorelin acts on the ghrelin receptor (GHS-R1a).
Produce + release: one signal drives GH synthesis, the other drives its secretion — they stack additively in models.
Selectivity: Ipamorelin keeps the pulse “clean,” with minimal cortisol or prolactin involvement.
Physiological feedback: the stack stimulates endogenous GH rather than bypassing it, preserving regulatory feedback in research systems.
Why it’s studied: combination models report larger GH elevations than either compound alone.
Format: both are supplied as lyophilized powders with batch-specific third-party analytics.

What is the CJC-1295 + Ipamorelin stack?

The stack is a research pairing of two distinct growth-hormone secretagogues that are studied together because their mechanisms overlap in effect but not in pathway. Each component plays a defined role:

CJC-1295 (No-DAC / Modified GRF 1-29) — a synthetic GHRH analog engineered to resist enzymatic degradation while preserving high-affinity binding at the GHRH receptor. It mimics the body’s own “produce more GH” signal.
Ipamorelin — a selective pentapeptide that binds the ghrelin receptor (GHS-R1a) and triggers GH release without significantly raising cortisol, prolactin, or appetite signaling.

NeuroPept Labs supplies both as research-grade lyophilized peptides verified through independent analytical testing. For a deeper look at the No-DAC form specifically, see our companion guide on CJC-1295 No-DAC vs DAC. A broader index of the published literature on this GHRH analog is available through the PubMed database.

Mechanism: two complementary signals

The reason this combination is studied so often comes down to receptor biology. The two compounds engage different cell-surface receptors on pituitary somatotrophs and converge on the same outcome — a GH pulse — through separate signaling routes:

CJC-1295 ? GHRH receptor. Activation raises intracellular cyclic AMP (cAMP), promoting GH synthesis and priming the somatotroph to release more hormone.
Ipamorelin ? ghrelin receptor (GHS-R1a). Activation drives phospholipase C signaling, inositol trisphosphate generation, and calcium mobilization, triggering release of stored GH.

When both receptors are engaged at once, the “produce” signal and the “release” signal reinforce each other. In published research models, the combination consistently elevates GH more than either compound on its own, which is the central observation motivating combination studies. Crucially, because Ipamorelin is selective, the amplified pulse is not accompanied by the cortisol and prolactin elevations seen with older, less selective growth hormone-releasing peptides.

Why the combination is studied: synergy in models

Researchers are interested in the stack because it produces a layered effect that single-pathway stimulation cannot replicate. The contrast is clearest when the approaches are placed side by side:

Approach	Primary signal	Typical observation in models
GHRH analog alone (CJC-1295)	“Produce” GH	Moderate, sustained GH increase
Ghrelin agonist alone (Ipamorelin)	“Release” GH	Discrete, short-lived GH pulse
CJC-1295 + Ipamorelin	Produce + release	Larger combined GH elevation than either alone

Several properties make this pairing attractive as a research tool:

Additive pathways — two receptors, two signaling cascades, one reinforced output.
Cleaner data — Ipamorelin’s selectivity limits confounding cortisol/prolactin shifts.
Extended window — CJC-1295’s longer functional duration overlaps Ipamorelin’s rapid pulse.
Comparability — a well-characterized stack serves as a benchmark for newer secretagogues.

Kinetic profiles: why timing matters

Part of what makes the pairing informative is that the two compounds operate on different timescales, so their effects overlap rather than simply adding at a single instant:

CJC-1295 No-DAC — produces a sustained signal that mimics the body’s pulsatile GHRH pattern, with a longer functional duration than a ghrelin agonist’s pulse.
Ipamorelin — produces a rapid-onset, short-lived release event rather than a prolonged elevation.
Overlap — when administered together in a model, the extended “produce” window coincides with the sharp “release” event, widening the combined signaling window.
Design implication — sampling intervals and the ratio between the two peptides are chosen around these differing kinetics so that the synergy can be measured cleanly.

This timescale difference is also why the stack is often contrasted with single-compound protocols: the combined kinetic profile is something neither peptide reproduces on its own.

Physiological feedback and research applications

A distinguishing feature of this stack in research is that it stimulates the body’s own GH machinery rather than replacing it. Because the somatotroph still controls the final release, models that use the combination retain native feedback loops — an important difference from approaches that introduce exogenous GH directly. This makes the pairing useful across several documented research directions:

Neuroendocrinology — modeling hypothalamic-pituitary-somatotropic axis regulation under dual stimulation.
Metabolic research — examining GH- and IGF-1-mediated signaling in glucose handling and lipolysis.
Receptor pharmacology — characterizing how GHRH-receptor and GHS-R1a activation interact.
Comparative studies — benchmarking combined versus single-pathway stimulation.

Within these areas, the endpoints researchers most often track help explain why a clean, reproducible pulse is so valuable:

GH pulse amplitude — the peak height of the combined release compared with single-compound controls.
IGF-1 dynamics — downstream signaling as a marker of sustained GH activity.
Off-target hormones — cortisol and prolactin, monitored to confirm selectivity is preserved.
Pulse duration — how long the combined signaling window remains elevated.

The selectivity that makes Ipamorelin valuable here was first established when it was introduced as the first selective growth hormone secretagogue, a property that still underpins its role in modern combination research.

Handling, reconstitution, and quality verification

Both peptides are supplied as lyophilized (freeze-dried) powders for stability. Because the integrity of each compound affects the validity of any combination study, careful handling is essential:

Storage (unreconstituted) — keep both lyophilized vials cold and protected from light until use.
Reconstitution — add diluent slowly down the vial wall and swirl gently rather than shaking.
Separate preparation — reconstitute and characterize each peptide individually so concentrations are known precisely.
Documentation — confirm a batch-specific certificate of analysis (COA) accompanies each compound.

Every NeuroPept Labs batch is synthesized under controlled conditions and accompanied by a COA. COA validity can be confirmed at freedomdiagnosticstesting.com using the Accession Number, Client ID, or Search Code found in the product images. For background on the analytics behind those documents, see our research-grade quality guide covering HPLC and mass spectrometry.

Considerations for experimental design

Because the value of the stack lies in a clean, amplified GH pulse, study design has an outsized effect on data quality. Researchers working with the combination commonly account for several variables:

Pulse timing — sampling windows are aligned to the expected combined peak rather than measured at arbitrary intervals.
Relative concentrations — the ratio of the two peptides is standardized across runs so synergy can be attributed rather than assumed.
Receptor desensitization — repeated GHRH-receptor and GHS-R1a stimulation can blunt responses, so washout intervals are controlled.
Baseline endocrine state — cortisol, prolactin, and IGF-1 baselines are characterized so selective effects can be isolated.
Model selection — somatotroph responsiveness differs across cell lines and animal models, affecting comparability.

These controls underscore why verified, high-purity starting material matters: batch-to-batch inconsistency in either peptide would undermine every downstream comparison the stack is designed to support.

Frequently asked questions

What does the CJC-1295 and Ipamorelin stack do in research?

In research models the combination stimulates a larger growth hormone pulse than either peptide alone by engaging two separate receptors — CJC-1295 on the GHRH receptor and Ipamorelin on the ghrelin receptor. It is studied as a tool for examining somatotropic-axis signaling and is intended for in vitro and laboratory research only.

Why are CJC-1295 and Ipamorelin used together?

They act on different receptors with complementary effects: CJC-1295 signals the pituitary to produce growth hormone, while Ipamorelin signals it to release stored growth hormone. Combining the “produce” and “release” signals reinforces the overall response in research models.

Does the stack raise cortisol or prolactin?

One reason this pairing is favored in research is that Ipamorelin is selective, so the amplified growth hormone pulse is generally not accompanied by the cortisol and prolactin elevations associated with older, less selective growth hormone-releasing peptides.

How is CJC-1295 No-DAC different from the DAC form?

CJC-1295 No-DAC lacks the albumin-binding Drug Affinity Complex, giving it a shorter, more pulsatile profile that mimics endogenous secretion, whereas the DAC form has a much longer duration. See our dedicated CJC-1295 No-DAC vs DAC guide for a full comparison.

What form do these peptides come in?

Both are supplied as lyophilized (freeze-dried) powders that are reconstituted before laboratory use and stored under refrigeration. Research-grade material should always be accompanied by a batch-specific certificate of analysis from an independent laboratory.

Is the CJC-1295 and Ipamorelin stack approved for human use?

No. These compounds offered for research are intended strictly for in vitro and laboratory investigation and are not approved for human consumption or clinical use. All information here is educational and not medical advice.

By NeuroPept Labs Research TeamIn CJC-1295, Growth Hormone Peptides, Ipamorelin, Research Peptides0 Comments

Ipamorelin vs Sermorelin vs CJC-1295: A Research Comparison

07/08/2026

Ipamorelin vs Sermorelin vs CJC-1295: A Research Comparison

Ipamorelin, Sermorelin, and CJC-1295 are three of the most studied growth hormone (GH) peptides in preclinical research, and they are often compared because they all increase GH — but they do not work the same way. Sermorelin and CJC-1295 are growth hormone-releasing hormone (GHRH) analogs that signal the pituitary to produce GH, while Ipamorelin is a selective ghrelin-receptor agonist that signals it to release GH. Understanding which receptor each one targets is the key to understanding how they differ in research.

Key takeaways

Two receptor families: Sermorelin and CJC-1295 act on the GHRH receptor; Ipamorelin acts on the ghrelin receptor (GHS-R1a).
Produce vs release: the GHRH analogs drive GH synthesis; Ipamorelin drives GH secretion.
Half-life: Sermorelin is very short-acting; CJC-1295 No-DAC lasts longer; Ipamorelin gives a rapid, selective pulse.
Selectivity: Ipamorelin is notable for minimal cortisol and prolactin involvement.
Why they are stacked: a GHRH analog plus Ipamorelin engages both pathways at once in research models.
Format: all are supplied as lyophilized powders with batch-specific third-party analytics.

The two pathways behind all three peptides

Every comparison of these compounds comes back to one distinction: which receptor the peptide engages on the pituitary somatotroph. There are two relevant systems, and the three peptides split across them:

The GHRH receptor — the target of the body’s own growth hormone-releasing hormone. Activating it raises cyclic AMP and tells the somatotroph to produce and prepare GH. Both Sermorelin and CJC-1295 work here.
The ghrelin receptor (GHS-R1a) — the target of ghrelin and of growth hormone-releasing peptides. Activating it drives calcium-dependent release of stored GH. Ipamorelin works here.

Because the two systems are independent, a “produce” signal and a “release” signal can be combined — which is exactly why combination research pairs a GHRH analog with Ipamorelin. For the GHRH side specifically, our guide on CJC-1295 No-DAC vs DAC covers the modifications in more detail.

Sermorelin: the short-acting GHRH analog

Sermorelin is a synthetic analog corresponding to the first 29 amino acids of human GHRH — the minimum fragment that retains full biological activity. In research models it produces a brief, sharp GH pulse and then clears quickly, with a functional half-life on the order of only ten to twelve minutes.

Mechanism — GHRH-receptor agonist; mimics the native “produce GH” signal.
Duration — very short; the pulse is rapid and transient.
Research role — often used as a baseline GHRH reference because it closely matches endogenous GHRH structure.

CJC-1295: the longer-acting GHRH analog

CJC-1295 is a modified GHRH analog engineered with amino-acid substitutions that resist enzymatic degradation while preserving high-affinity binding at the GHRH receptor. The No-DAC form (also called Modified GRF 1-29) lacks the albumin-binding Drug Affinity Complex, giving it a pharmacokinetic profile that still mimics pulsatile secretion but lasts noticeably longer than Sermorelin.

Mechanism — GHRH-receptor agonist with enhanced stability.
Duration — longer functional window than Sermorelin; a more sustained “produce” signal.
Research role — a frequent partner for Ipamorelin because its extended signal overlaps Ipamorelin’s sharp pulse.

The broader literature on this analog is indexed in the PubMed database for researchers comparing GHRH modifications.

Ipamorelin: the selective ghrelin-receptor agonist

Ipamorelin is the outlier of the three. Rather than acting on the GHRH receptor, it binds the ghrelin receptor (GHS-R1a) and triggers GH release through a separate calcium-dependent cascade. It was introduced as the first selective growth hormone secretagogue, distinguished from older peptides by minimal cortisol and prolactin involvement.

Mechanism — ghrelin-receptor (GHS-R1a) agonist; drives release of stored GH.
Duration — rapid onset, short-lived pulse.
Research role — the selective “release” partner in combination studies, and a benchmark for the selectivity of newer secretagogues.

Side-by-side comparison

Placed in one table, the differences are straightforward:

Peptide	Receptor	Signal	Relative duration	Selectivity note
Sermorelin	GHRH receptor	Produce GH	Very short (~10-12 min)	Native GHRH fragment
CJC-1295 (No-DAC)	GHRH receptor	Produce GH	Longer, sustained	Degradation-resistant analog
Ipamorelin	Ghrelin receptor (GHS-R1a)	Release GH	Rapid, short pulse	Minimal cortisol/prolactin

Reading the table, a few practical points stand out for study design:

Different axes: comparing Ipamorelin directly against the GHRH analogs is comparing two mechanisms, not two versions of one.
Duration shapes sampling: the short Sermorelin pulse and the longer CJC-1295 window call for different measurement timing.
Selectivity shapes interpretation: Ipamorelin’s clean profile reduces confounding hormone shifts.

Why researchers combine a GHRH analog with Ipamorelin

Because the GHRH receptor and the ghrelin receptor are separate, a GHRH analog and Ipamorelin can be studied together to engage both at once. In published models this combined stimulation produces a larger GH elevation than either pathway alone, while Ipamorelin’s selectivity keeps the amplified pulse from being accompanied by cortisol and prolactin spikes. Common research motivations include:

Pathway interaction — characterizing how “produce” and “release” signals reinforce each other.
Feedback preservation — the somatotroph still governs release, retaining native feedback.
Benchmarking — a well-defined combination serves as a reference for new compounds.

This is why the comparison rarely ends with “which is best”: in research, the three are often complementary tools rather than competitors.

Choosing the right tool for a research question

Because these peptides are mechanistically distinct, the most useful one depends entirely on the question a study is asking rather than on any ranking of potency:

Studying the GHRH receptor — Sermorelin or CJC-1295 are the natural choices, with the former offering a native-like short pulse and the latter a longer, more stable signal.
Studying selective GH release — the ghrelin-receptor route isolates secretion without engaging the GHRH pathway at all.
Studying pathway interaction — a GHRH analog combined with the ghrelin-receptor agonist lets both systems be observed at once.
Studying selectivity itself — the minimal cortisol and prolactin profile of the ghrelin-receptor agonist makes it a useful control against less selective peptides.

Framed this way, the comparison is less about which peptide “wins” and more about matching a receptor mechanism to an experimental endpoint — the same logic that guides any well-designed pharmacology study. It also explains why so many protocols end up using more than one of these compounds rather than settling on a single favorite.

Handling, reconstitution, and quality verification

All three peptides are supplied as lyophilized powders, and the integrity of each affects any comparison drawn between them:

Storage — keep lyophilized vials cold and protected from light until use.
Reconstitution — add diluent slowly down the vial wall and swirl gently, never shake.
Characterize separately — prepare each compound individually so concentrations are known precisely.
Documentation — confirm a batch-specific certificate of analysis (COA) for each.

Every NeuroPept Labs batch is synthesized under controlled conditions and accompanied by a COA, verifiable at freedomdiagnosticstesting.com using the codes in the product images. Both Ipamorelin and CJC-1295 No-DAC are supplied as research-grade material with independent analytics.

Considerations for experimental design

When the goal is to compare these peptides, controlling for their mechanistic differences matters more than anything else:

Match the endpoint — GH pulse amplitude, duration, and downstream IGF-1 should be measured consistently across all arms.
Time to mechanism — sampling windows reflect each peptide’s kinetics rather than a single fixed schedule.
Isolate the variable — when testing a combination, single-compound controls clarify what the stack adds.
Verify purity first — differences between peptides are only meaningful if each is high-purity and accurately quantified.

In short, a clean comparison depends as much on disciplined methodology and verified starting material as it does on the peptides themselves. Two studies using the same three compounds can reach different conclusions simply because of how timing, concentration, and material quality were controlled — which is why reproducibility, not raw potency, is the standard that matters most in this kind of research.

Frequently asked questions

What is the main difference between Ipamorelin and Sermorelin?

Ipamorelin acts on the ghrelin receptor (GHS-R1a) to release stored growth hormone, while Sermorelin is a GHRH analog that acts on the GHRH receptor to stimulate growth hormone production. They engage different receptor systems, which is the core distinction in research.

Is CJC-1295 stronger than Sermorelin?

Both are GHRH analogs, but CJC-1295 No-DAC is engineered to resist degradation and has a longer functional duration than Sermorelin, producing a more sustained signal in research models. Sermorelin more closely matches the native GHRH structure and clears faster.

Why is Ipamorelin often compared to GHRH analogs?

Because all three raise growth hormone, they are grouped together — but Ipamorelin does so through a different receptor than Sermorelin and CJC-1295. The comparison highlights that it is a complementary “release” signal rather than another “produce” signal.

Can these peptides be studied together?

Yes. In research models a GHRH analog such as CJC-1295 is frequently paired with Ipamorelin so that both the GHRH receptor and the ghrelin receptor are engaged at once, producing a larger combined growth hormone response than either alone.

What form do these peptides come in?

All three are supplied as lyophilized (freeze-dried) powders that are reconstituted before laboratory use and stored under refrigeration, and each should be accompanied by a batch-specific certificate of analysis from an independent laboratory.